ECSP077262A - Composicion antihistaminica - Google Patents
Composicion antihistaminicaInfo
- Publication number
- ECSP077262A ECSP077262A EC2007007262A ECSP077262A ECSP077262A EC SP077262 A ECSP077262 A EC SP077262A EC 2007007262 A EC2007007262 A EC 2007007262A EC SP077262 A ECSP077262 A EC SP077262A EC SP077262 A ECSP077262 A EC SP077262A
- Authority
- EC
- Ecuador
- Prior art keywords
- desloratadine
- composition
- polyol
- composition consisting
- antihistaminal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 abstract 4
- 229960001271 desloratadine Drugs 0.000 abstract 4
- 229920005862 polyol Polymers 0.000 abstract 4
- 150000003077 polyols Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una composición farmacéutica estable que consiste de desloratadina ó una sal, solvato, derivado, polimorfo, hidrato ó enantiómero de la misma, y un portador que consiste de por lo menos un poliol. Las composiciones preferidas consisten de, además de la desloratadina, desde 50 hasta 80% de poliol, desde 5 hasta 15% de agente desintegrante, y desde 0,01 hasta 0,5% de un antioxidante y/ó un agente de quelación, todos por peso de la composición.También se provee para el uso de un poliol para estabilizar una composición farmacéutica que consiste de desloratadina.Un proceso para hacer una composición farmacéuticamente estable que consiste de desloratadina y uno ó más polioles, opcionalmente junto con otros excipientes farmacéuticamente aceptables, que consiste en combinar los ingredientes y formularlos para formar dicha composición.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN765MU2004 | 2004-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP077262A true ECSP077262A (es) | 2007-03-29 |
Family
ID=35539416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2007007262A ECSP077262A (es) | 2004-07-16 | 2007-02-16 | Composicion antihistaminica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070281960A1 (es) |
| EP (1) | EP1778195A2 (es) |
| JP (1) | JP2008506679A (es) |
| KR (1) | KR20070053221A (es) |
| AP (1) | AP2007003915A0 (es) |
| AU (1) | AU2005263958B2 (es) |
| BR (1) | BRPI0513417A (es) |
| CA (1) | CA2574188A1 (es) |
| EC (1) | ECSP077262A (es) |
| IL (1) | IL180724A0 (es) |
| MA (1) | MA28801B1 (es) |
| MX (1) | MX2007000632A (es) |
| NZ (1) | NZ552998A (es) |
| TN (1) | TNSN07013A1 (es) |
| WO (1) | WO2006008512A2 (es) |
| ZA (1) | ZA200701036B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2276801A (en) * | 1999-12-20 | 2001-07-03 | Schering Corporation | Extended release oral dosage composition |
| PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
| ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
| ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
| GB0702837D0 (en) * | 2007-02-14 | 2007-03-28 | Boc Group Plc | Method of treating a gas stream |
| CN101678012A (zh) * | 2007-06-12 | 2010-03-24 | 阿尔克-阿贝洛有限公司 | 包含抗组胺药的过敏原剂型 |
| TR200806298A2 (tr) | 2008-08-22 | 2010-03-22 | Bi̇lgi̇ç Mahmut | Farmasötik formülasyon |
| ES2709487T3 (es) | 2010-05-10 | 2019-04-16 | Lesvi Laboratorios Sl | Formulaciones farmacéuticas estables que contienen un antihistamínico |
| JP6072778B2 (ja) * | 2011-05-23 | 2017-02-01 | シーイーエム—102 ファーマシューティカルズ,インコーポレイテッド | フシジン酸を含む組成物およびそのためのパッケージ |
| CN109498585B (zh) * | 2018-12-21 | 2019-09-10 | 扬子江药业集团广州海瑞药业有限公司 | 一种枸地氯雷他定片剂及其制备方法 |
| JP7515533B2 (ja) * | 2022-04-28 | 2024-07-12 | 沢井製薬株式会社 | デスロラタジン含有フィルムコーティング錠剤 |
| CN118924679B (zh) * | 2024-07-24 | 2025-05-16 | 湖南派格兰药业有限公司 | 一种氨甲环酸凝胶组合物及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU194864B (en) * | 1984-02-15 | 1988-03-28 | Schering Corp | Process for production of 8-chlor-6,11-dihydro-11-(4-piperidilidene)-5h-benzo (5,6)-cyclo-hepta (1,2-b) pyridine and its salts |
| US5595997A (en) * | 1994-12-30 | 1997-01-21 | Sepracor Inc. | Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine |
| TW522014B (en) * | 1997-02-07 | 2003-03-01 | Sepracor Inc | Lactose-free, non-hygroscopic and anhydrous pharmaceutical unit dosage form containing descarboethoxyloratadine |
| US5939426A (en) * | 1997-02-28 | 1999-08-17 | Sepracor Inc. | Methods for treating urinary incontinence using descarboethoxyloratadine |
| CA2288726C (en) * | 1997-04-25 | 2008-04-01 | Schering-Plough Kabushiki Kaisha | Eyedrops containing a loratadine metabolite |
| US6506767B1 (en) * | 1997-07-02 | 2003-01-14 | Schering Corporation | 8-chloro-6,11-dihydro-11-(4-piperidylidine)-5H-benzo[5,6]cyclohepta[1-2-b] pyridine |
| CA2325014C (en) * | 1998-07-10 | 2002-05-28 | Schering Corporation | 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]pyridine oral compositions |
| US6100274A (en) * | 1999-07-07 | 2000-08-08 | Schering Corporation | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
| AU2002342577B2 (en) * | 2002-09-24 | 2008-05-15 | Gumlink A/S | Low moisture chewing gum |
| US20040258752A1 (en) * | 2003-01-31 | 2004-12-23 | Paruthi Manoj Kumar | Taste masking pharmaceutical composition and process for its preparation |
| CN100563654C (zh) * | 2003-07-22 | 2009-12-02 | 范敏华 | 一种地氯雷他定分散片及其制备方法 |
| GB2404336A (en) * | 2003-07-30 | 2005-02-02 | Cipla Ltd | Stabilisation of therapeutic agents using a carbonate salt of an amino acid, preferably in the presence of a saccharide, & pharmaceutical compositions thereof |
| WO2005065047A2 (en) * | 2003-12-23 | 2005-07-21 | Sun Pharmaceutical Industries Limited | Stable oral composition containing desloratadine |
-
2005
- 2005-07-18 ZA ZA200701036A patent/ZA200701036B/en unknown
- 2005-07-18 JP JP2007520903A patent/JP2008506679A/ja active Pending
- 2005-07-18 NZ NZ552998A patent/NZ552998A/en not_active IP Right Cessation
- 2005-07-18 CA CA002574188A patent/CA2574188A1/en not_active Abandoned
- 2005-07-18 AP AP2007003915A patent/AP2007003915A0/xx unknown
- 2005-07-18 WO PCT/GB2005/002828 patent/WO2006008512A2/en not_active Ceased
- 2005-07-18 US US11/572,175 patent/US20070281960A1/en not_active Abandoned
- 2005-07-18 MX MX2007000632A patent/MX2007000632A/es not_active Application Discontinuation
- 2005-07-18 KR KR1020077003510A patent/KR20070053221A/ko not_active Ceased
- 2005-07-18 AU AU2005263958A patent/AU2005263958B2/en not_active Ceased
- 2005-07-18 EP EP05761371A patent/EP1778195A2/en not_active Withdrawn
- 2005-07-18 BR BRPI0513417-0A patent/BRPI0513417A/pt not_active IP Right Cessation
-
2007
- 2007-01-16 TN TNP2007000013A patent/TNSN07013A1/en unknown
- 2007-01-16 IL IL180724A patent/IL180724A0/en unknown
- 2007-02-13 MA MA29679A patent/MA28801B1/fr unknown
- 2007-02-16 EC EC2007007262A patent/ECSP077262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20070281960A1 (en) | 2007-12-06 |
| NZ552998A (en) | 2010-11-26 |
| CA2574188A1 (en) | 2006-01-26 |
| BRPI0513417A (pt) | 2008-05-06 |
| KR20070053221A (ko) | 2007-05-23 |
| ZA200701036B (en) | 2008-05-28 |
| WO2006008512A2 (en) | 2006-01-26 |
| JP2008506679A (ja) | 2008-03-06 |
| EP1778195A2 (en) | 2007-05-02 |
| WO2006008512A3 (en) | 2006-08-03 |
| AP2007003915A0 (en) | 2007-02-28 |
| IL180724A0 (en) | 2007-07-04 |
| AU2005263958A1 (en) | 2006-01-26 |
| MX2007000632A (es) | 2007-03-30 |
| AU2005263958B2 (en) | 2011-04-14 |
| MA28801B1 (fr) | 2007-08-01 |
| TNSN07013A1 (en) | 2008-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP077262A (es) | Composicion antihistaminica | |
| ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
| AR056873A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas | |
| AR055076A1 (es) | Derivados de1,1-dioxido de 1,4-benzotiazepina,procedimiento para prepararlos,composiciones farmaceuticas que los contienen y usos en terapeutica. | |
| AR055070A1 (es) | Una composicion farmaceutica de liberacion sostenida, proceso para la preparacion de dicha composicion, metodo para la utilizacion de la misma y su uso | |
| CR10549A (es) | Composicion farmaceutica que contienen un acido tetrahidrofolico | |
| AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
| MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
| PA8586401A1 (es) | 4-piperazinilbencenosulfonilindoles y uso de los mismos | |
| ECSP088511A (es) | Agonistas del receptor del neuropeptido-2 | |
| ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| UY27446A1 (es) | Nuevos compuestos | |
| SV2003000697A (es) | Agonistas del receptor beta3-adrenergico y usos de los mismos ref. pc11008/700016/bb | |
| PE20120476A1 (es) | Composiciones farmaceuticas estabilizadas que comprenden fesoterodina | |
| SV2004001418A (es) | Formulaciones farmaceuticas de 5,7,14-triazaciclo 10.3.1.0.2,11.04,9) -hexadeca-2(11),3,5,7,9-pentaeno" ref.pc 23248 | |
| MX2009003735A (es) | Composicion en deposito inyectable y su procedimiento de preparacion. | |
| EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
| AR062397A1 (es) | Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| AR040434A1 (es) | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco | |
| AR020032A1 (es) | Derivados de 1,3 -metil eritromicina. | |
| WO2006081363A3 (en) | Oral formulations for delivery of catecholic butanes including ndga compounds | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| PA8568101A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов |